12. Commitments and Contingencies (Details Narrative) (USD $)
|
12 Months Ended | |
---|---|---|
Mar. 31, 2015
|
Mar. 31, 2014
|
|
Rent expense | $ 446,000us-gaap_LeaseAndRentalExpense | $ 413,000us-gaap_LeaseAndRentalExpense |
Potential severance | 1,130,000us-gaap_SeveranceCosts1 | |
Aggregated annual salaries | 935,000us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent | |
Service fees received | 41,000us-gaap_OtherSalesRevenueNet | |
Innovacyn | ||
Accounts receivable |
3,000us-gaap_AccountsReceivableRelatedParties / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_InnovacynMember |
220,000us-gaap_AccountsReceivableRelatedParties / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_InnovacynMember |
More Pharma | ||
Accounts receivable |
609,000us-gaap_AccountsReceivableRelatedParties / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
|
Amortization of transaction fees |
63,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
63,000us-gaap_AmortizationOfDeferredCharges / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
Transaction costs |
1,499,000us-gaap_DebtIssuanceCosts / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
1,501,000us-gaap_DebtIssuanceCosts / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_MorePharmaMember |
Vetericyn and Innovacyn | ||
Revenue earned |
1,120,000us-gaap_ContractsRevenue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
3,100,000us-gaap_ContractsRevenue / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_VetericynAndInnovacynMember |
Laboratorios Sanfer | ||
Accounts receivable |
$ 843,000us-gaap_AccountsReceivableRelatedParties / us-gaap_RelatedPartyTransactionsByRelatedPartyAxis = ocls_LaboratoriosSanferMember |
X | ||||||||||
- Definition
For an unclassified balance sheet, amount of receivables arising from transactions with related parties. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The amount of amortization of deferred charges applied against earnings during the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees). No definition available.
|
X | ||||||||||
- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. No definition available.
|
X | ||||||||||
- Definition
Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|